Compare Neurocrine Biosciences Inc (NBIX) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.43 (market cap $962.24M). The key difference: Neurocrine Biosciences Inc is far larger — about 14.9× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Roundhill Innov-100 0DTE Covered Call Strat ETF is more actively traded (882,859 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 56 Days on average.
| NBIX | QDTE | |
|---|---|---|
Market Cap | $14.36B | $962.24M |
Volume | 1,237,180 | 882,859 |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $36.60 |
52-Week Low | $123.10 | $26.85 |
Typical Hold Time | 23 Days | 56 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
QDTE trades at $29.89, down 0.3% with a bullish technical signal despite overbought RSI readings. The ETF generates weekly income through covered call strategies but faces concerns about NAV erosion and return of capital. Recent distributions have declined from $0.28 to $0.11, reflecting shrinking yields as volatility decreases. The fund's 0.97% expense ratio consumes significant portions of payouts, creating structural challenges for long-term value preservation.
The outlook remains cautious as high distribution yields mask underlying NAV deterioration. While weekly income appeals to retail investors, the strategy underperforms in bull markets and faces sustainability questions. Key risks include volatility dependency, return of capital concerns, and competitive pressure from alternative income ETFs. Analyst sentiment is mixed with recent downgrades highlighting structural weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
